Compare KLA Corp. (KLAC) vs Medpace Holdings Inc (MEDP) Price & Performance

KLA Corporation (KLAC) trades at $217.56, up 2.26% today, showing strong momentum after recent earnings beats. The stock maintains bullish technical signals with RSI levels indicating potential oversold conditions. Fundamentally, KLAC demonstrates robust profitability with 35.66% net income margin and consistent revenue growth, though valuation ratios remain elevated. Recent corporate actions include a 1:10 stock split and $2.30 dividend payment, reflecting management confidence.

KLAC presents a compelling growth story with dominant semiconductor process control positioning, but faces valuation concerns and sector volatility risks. Analyst consensus remains bullish with $242.49 price target, though near-term headwinds from semiconductor market correction require careful monitoring. The company's strong cash flow generation and AI-driven equipment demand support long-term upside potential.

MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.

The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.